Treatment patterns and impact of glucocorticoids on health outcomes in generalized myasthenia gravis: a retrospective observational study based on the Medical Data Vision database in Japan

Most patients were treated with AChEi, GC, or NSIST monotherapy or combination therapies and received GCs exceeding 5 mg/day, which was associated with developing several GC-associated comorbidities in a dose-dependent manner. To achieve treatment goals, patients with gMG may benefit from additional treatment approaches to reduce GC usage.